Tolerability of re-vaccination
Of the 214 patients showing any symptom in line with a possible allergic
reaction after the first vaccination, 71 patients did not show any
immediate allergic symptoms after re-vaccination with the identical
(n=57) or a non-identical SARS-CoV-2 vaccine (n=13) and for one patient
the type of the second vaccine is unknown. Six further patients showed
similar tolerability to re-vaccination and one patient had urticarial
after the re-vaccination. In some of the above mentioned cases, the
second dose was given fractionated (n=9), in other cases, the
vaccination was given as a whole dose with extended emergency
preparedness and some patients received premedication before vaccination
(n=3) (antihistamines and oral corticosteroids).
Finally, two cases were identified for which the vaccination with the
approved SARS-CoV-2 vaccinations is contraindicated. Five patients
denied revaccination, one patient denied completely the vaccination and
one patient died (due to other medical reasons) and could not be
revaccinated. For one patient the re-vaccination was not applicable, due
to previous COVID-19 Infection.
The allergy workup revealed from a total of 334 patients in 57 cases
(17%) a suspicion of type 1 sensitization against the SARS-CoV-vaccine
and/or the excipients defined as one positive skin test and/or basophil
activation test. A re-vaccination with any available SARS-CoV-2 vaccine
of patients from this group was contraindicated in one case only, due to
SPT positivity to several vaccines. 27/57 patients were successfully
re-vaccinated (26 with the identical vaccine). Three patients denied
completely the vaccination, in one patient of these the re-vaccination
was not necessary, due to previous COVID-19 infection and one patient
died (due to other medical reasons).